P2X7受体在癌痛中作用的研究进展

doi:10.16352/j.issn.1001-6325.2024.03.0389

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (3): 389-392.doi: 10.16352/j.issn.1001-6325.2024.03.0389

P2X7受体在癌痛中作用的研究进展

张忠文¹, 赵瑞², 张浩龙³, 杨钰婷⁴, 白金霞⁴, 张浩令^3*, 王薇^4*

甘肃中医药大学 1.公共卫生学院;2.中医临床学院;4.针灸推拿学院,甘肃兰州 730000;
3.马来西亚理科大学高级医学与牙科研究所,马来西亚槟城 13200

收稿日期:2023-06-07 修回日期:2023-12-01 出版日期:2024-03-05 发布日期:2024-02-22
通讯作者: ^*:wangwei@gszy.edu.cn;zhanghaolingedu@163.com
基金资助:
甘肃省自然科学基金(22JR5RA582,21JR1RA267);甘肃省高等学校创新基金(2023A-088);甘肃省中医药研究中心专项开放课题(zyzx-2020-zx10);甘肃省教育科技创新项目(2022A-067)

Research progress on P2X7 receptor in cancer pain

ZHANG Zhongwen¹, ZHAO Rui², ZHANG Haolong³, YANG Yuting⁴, BAI Jinxia⁴, ZHANG Haoling^3* WANG Wei^*

1. School of Public Health; 2. Clinical College of Chinese Medicine; 4. College of Acupuncture-Moxibustion and Tuing, Gansu University of Chinese Medicine, Lanzhou 730000, China;
3. Advanced Medical and Dental Institute, University Sains Malaysia,Penang 13200, Malaysia

Received:2023-06-07 Revised:2023-12-01 Online:2024-03-05 Published:2024-02-22
Contact: ^*:wangwei@gszy.edu.cn;zhanghaolingedu@163.com

摘要/Abstract

摘要： P2X7受体是一种ATP门控离子通道,在肿瘤条件下,P2X7受体的激活触发了促炎细胞因子的释放,刺激了伤害性神经元的兴奋,从而加剧了疼痛的传递。在临床前癌疼痛模型中,具有作为癌疼痛管理的新治疗靶点的潜力。

关键词: P2X7受体, 癌痛, 神经胶质细胞, P2X7拮抗剂

Abstract: The activation of the P2X7 receptor as an ATP-gated ion channel, triggers the release of pro-inflammatory cytokines in tumor carring individuals and stimulate excitation of injury-causing neurons, thereby exacerbating the transmission of pain. In preclinical cancer pain models, it has the potential to serve as a new therapeutic target for cancer pain management.

Key words: P2X7 receptor, cancer pain, glial cell, P2X7 antagonist

中图分类号:

R737.9

张忠文, 赵瑞, 张浩龙, 杨钰婷, 白金霞, 张浩令, 王薇. P2X7受体在癌痛中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 389-392.

ZHANG Zhongwen, ZHAO Rui, ZHANG Haolong, YANG Yuting, BAI Jinxia, ZHANG Haoling WANG Wei. Research progress on P2X7 receptor in cancer pain[J]. Basic & Clinical Medicine, 2024, 44(3): 389-392.

参考文献 26

[1]	Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain[J]. Pain Med, 2019, 20: S2-S12.
[2]	刘强,邱东宇,菅敏钰,等.吗啡通过激活ERK1/2信号通路促进胶质母细胞瘤细胞增殖[J].基础医学与临床,2018,38:507-511.
[3]	Marchesi N, Govoni S, Allegri M. Non-drug pain relievers active on non-opioid pain mechanisms[J]. Pain Practice, 2022, 22: 255-275.
[4]	Scarpellino G, Genova T, Munaron L. Purinergic P2X7 receptor: a cation channel sensitive to tumor microenvironment[J]. Recent Pat Anti Drug Discov, 2019,14:32-38.
[5]	Drill M, Jones NC, Hunn M, et al. Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer[J]. Purinergic Signal, 2021, 17: 215-227.
[6]	Song JG, Liu L. Naringenin alleviates bone cancer pain in rats via down-regulating spinal P2X7R/PI3K/AKT signaling: involving suppression in spinal inflammation[J]. Mol Cell Toxicol, 2021, 17: 475-484.
[7]	Jiang LH, Caseley EA, Muench SP, et al. Structural basis for the functional properties of the P2X7 receptor for extracellular ATP[J]. Purinergic Signal, 2021, 17: 331-344.
[8]	von Mücke-Heim IA, Deussing JM. The P2X7 receptor in mood disorders: emerging target in immunopsychiatry, from bench to bedside[J]. Neuropharmacology, 2022: 109366.doi: 0.1016/j.neuropharm.2022.109366.
[9]	Kan LK, Williams D, Drummond K, et al. The role of microglia and P2X7 receptors in gliomas[J]. J Neuroimmunol, 2019, 332: 138-146.
[10]	Wu Y, Shen Z, Xu H, et al. BDNF participates in chronic constriction injury-induced neuropathic pain via transcriptionally activating P2X7 in primary sensory neurons[J]. Mol Neurobiol, 2021, 58: 4226-4236.
[11]	Dong Y, Chen Y, Zhang L, et al. P2X7 receptor acts as an efficient drug target in regulating bone metabolism system[J]. Biomed Pharmacother, 2020, 125: 110010.doi: 10.1016/j.biopha.2020.110010.
[12]	Platania CBM, Lazzara F, Fidilio A, et al. Blood-retinal barrier protection against high glucose damage: the role of P2X7 receptor[J]. Biochem Pharmacol, 2019, 168: 249-258.
[13]	Zhang W, Hu C, Zhu Z, et al. Effect of P2X7 receptor on tumorigenesis and its pharmacological properties[J]. Biomed Pharmacother, 2020, 125: 109844.doi: 10.1016/j.biopha.2020.109844.
[14]	Felix R, Muñoz-Herrera D, Corzo-López A, et al. Ion channel long non-coding RNAs in neuropathic pain[J]. Pflugers Arch, 2022, 474: 457-468.
[15]	McGinnis A, Ji RR. The similar and distinct roles of satellite glial cells and spinal astrocytes in neuropathic pain[J]. Cells, 2023, 12: 965.doi: 10.3390/cells12060965.
[16]	Bravo D, Zepeda-Morales K, Maturana CJ, et al. NMDA and P2X7 receptors require pannexin 1 activation to initiate and maintain nociceptive signaling in the spinal cord of neuropathic rats[J]. Int J Mol Sci, 2022, 23: 6705.doi: 10.3390/ijms23126705.
[17]	Zhou J, Zhang X, Zhou Y, et al. Up-regulation of P2X7 receptors contributes to spinal microglial activation and the development of pain induced by BmK-I[J]. Neurosci Bull, 2019, 35: 624-636.
[18]	Wu P, Wu X, Zhou G, et al. P2X7 receptor-induced bone cancer pain by regulating microglial activity via NLRP3/IL-1beta signaling[J]. Pain Physician, 2022, 25(8): E1199-E1210.
[19]	Wu P, Wang Y, Liu Y, et al. Emerging roles of the P2X7 receptor in cancer pain[J]. Purinergic Signal, 2022: 1-10.
[20]	Zou Y, Yang R, Li L, et al. Purinergic signaling: a potential therapeutic target for depression and chronic pain[J]. Purinergic Signal, 2021: 1-10.
[21]	Zhang W, Zhu Z, Liu Z. The role and pharmacological properties of the P2X7 receptor in neuropathic pain[J]. Brain Res Bull, 2020, 155: 19-28.
[22]	Oskolkova OV, Godschachner V, Bochkov VN. Off-target anti-inflammatory activity of the p2x7 receptor antagonist AZ11645373[J]. Inflammation, 2017, 40: 530-536.
[23]	Honore P, Donnelly-Roberts D, Namovic MT, et al. A-740003[N-(1-{[(cyanoimino)(5-quinolinylamino) methyl] amino}-2, 2-dimethylpropyl)-2-(3, 4-dimethoxyphenyl) acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat[J]. J Pharmacol Exp Ther, 2006, 319: 1376-1385.
[24]	Yue N, Huang H, Zhu X, et al. Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippo-campal glial cells mediates chronic stress-induced depressive-like behaviors[J]. J Neuroinflammation, 2017, 14: 1-15.
[25]	Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone[J]. Cancer Res, 2005, 65: 9426-9435.
[26]	Jelassi B, Anchelin M, Chamouton J, et al. Anthraquin-one emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors[J]. Carcinogenesis, 2013, 34: 1487-1496.

P2X7受体在癌痛中作用的研究进展

Research progress on P2X7 receptor in cancer pain

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 3

编辑推荐

Metrics

本文评价

[1]	周佳宏, 李民. 肿瘤微环境在骨癌痛中作用的新进展[J]. 基础医学与临床, 2021, 41(3): 448-451.
[2]	崔丽, 于壮. 胃复安预防羟考酮诱导的恶心呕吐的前瞻性观察[J]. 基础医学与临床, 2020, 40(9): 1201-1205.
[3]	王小娟, 李小丽, 金正旭, 张德奎. GDNF与消化系统肿瘤关系研究进展[J]. 基础医学与临床, 2020, 40(7): 986-989.